Cardiotoxins, Heart Failure, Systolic, Multiple Myeloma
Conditions
Brief summary
The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here. The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.
Interventions
DRUGBortezomib
Sponsors
Millennium: The Takeda Oncology Company
Oregon Health and Science University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of multiple myeloma * have a treatment plan involving greater than 4 cycles of bortezomib-based chemotherapy
Exclusion criteria
* pre-existing history of left ventricular systolic dysfunction * congestive heart failure * coronary artery disease * significant valvular heart disease * cardiac arrhythmias * estimated glomerular filtration rate \<30 mL/min/1.73m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global longitudinal strain by echocardiography | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| High-sensitivity troponin T | 6 months |
| C-reactive protein | 6 months |
| Amount of late gadolinium enhancement by cardiac MRI | 6 months |
| Carboxyl-terminal telopeptide of collagen type I | 6 months |
| Amino-terminal peptide of procollagen type III | 6 months |
| Serum NT-proBNP | 6 months |
Outcome results
None listed